Omaveloxolone attenuates squamous cell carcinoma growth and disease severity in an Epidermolysis Bullosa mouse model. Issue 7 (31st March 2022)

• Record Type: Journal Article
• Authors: Cohen‐Nowak, Adam J.; Cohen, Alexa J.; Correia, Emily D.; Portocarrero, Carla P.; South, Andrew P.; Nikbakht, Neda
• Is Part Of: Experimental dermatology. Volume 31:Issue 7(2022)
• Page Start: 1083
• Page End: 1088
• Publication Date: 2022-03-31
• Subjects: epidermolysis bullosa -- mouse model -- Omaveloxolone -- squamous cell carcinoma -- triterpenoids; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.14564
• Languages: English
• ISSNs: 0906-6705

Abstract

Abstract: Patients with epidermolysis bullosa (EB) are susceptible to development of squamous cell carcinomas (SCC) at sites of chronic inflammation and fibrosis. While triterpenoids such as RTA 408 (Omaveloxolone) have been shown to reduce inflammation and inhibit tumour growth in various cancer models, the utility of this class of drugs in the treatment of SCC has not been investigated. Given the dual anti‐inflammatory and anti‐neoplastic properties of triterpenoids, we hypothesized RTA 408 would be an effective treatment for SCCs that arise in the chronic inflammatory setting in EB. We tested the effects of topical RTA 408 on a mouse model of non‐Herlitz, junctional EB. RTA 408 significantly reduced phenotypic severity in the affected ears of Lamc2 jeb mice. In cultures, RTA 408 reduced cell viability in EB‐associated SCC cell lines and normal human epidermal keratinocytes. When administered in vivo, RTA 408 inhibited SCC tumour growth in mice without cutaneous or systemic toxicity. These results suggest that RTA 408 can be a promising new therapy to reduce inflammation and inhibit SCC growth in patients with EB.